U.S.BiotechnologyandEuropeanPharmaRheumatologyExpertCallTranscriptPharmaceuticals&Biotechnology|ConferenceCallWehostedanexpertphysiciancallwithrheumatologistDr.StevenGolombekofAllergyAsthma&ArthritisAssociatesbasedinNewJerseytodiscussthetreatmentlandscape(currentandemerging)forrheumatoidarthritis,psoriaticarthritis,andotherrheumaticdiseases.Areplayofthecallisavailable:(855)859-2056//(404)537-3406;ID:1656826.Wehaveincludedthefulltranscriptofthecallinthisdocument.Areplayofthecallisavailable:(855)859-2056//(404)537-3406;ID:1656826.21May2020EquityResearchAmericas|UnitedStatesDISCLOSUREAPPENDIXATTHEBACKOFTHISREPORTCONTAINSIMPORTANTDISCLOSURES,ANALYSTCERTIFICATIONS,LEGALENTITYDISCLOSUREANDTHESTATUSOFNON-USANALYSTS.USDisclosure:CreditSuissedoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethattheFirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.ResearchAnalystsEvanSeigerman2123254463evan.seigerman@credit-suisse.comEuropeanPharmaTeam442078880304creditsuisse.pharmateam@credit-suisse.com21May2020U.S.BiotechnologyandEuropeanPharma2CREDITSUISSESECURITIES,LLCModerator:EvanSeigermanMay21,202010:00a.m.ETOperator:ThisisConference#:1656826Operator:Ladiesandgentlemen,thankyouforstandingbyandwelcometotheRheumatologistExpertCalltoDiscussCurrentandEmergingTherapeutics.Atthistime,allparticipantsareinalisten-onlymode.Afterthespeakerpresentation,therewillbeaquestionandanswersession.Toaskaquestionduringthissession,youwillneedtopress"star""one"onyourtelephone.Pleasebeadvisedthattoday'sconferenceisbeingrecorded.Ifyourequirefurtherassistance,pleasepress"star""zero."Iwouldnowliketohandtheconferenceovertoyourspeakertoday,EvanSeigerman.Thankyou.Pleasegoahead,sir.EvanSeigerman:Thankyou,Operator.Andthankyou,everyone,forjoiningustoday.Ontheline,IhavemycolleaguesinEurope,ElizabethWaltonandJoWalton,andmyteam,AdrianGarciaandMattTerwelp.Andwealsohave...
